Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL’s International Liver Congress™ 2022
LAVAL, QC, June 20, 2022 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals, (“Salix”), one of the largest specialty pharmaceutical companies in the world committed…
SALIX PHARMACEUTICALS WILL PRESENT SCIENTIFIC DATA AT THE SOCIETY OF HOSPITAL MEDICINE CONVERGE 2022
Featured Posters Will Include XIFAXAN® (rifaximin) and RELISTOR® (methylnaltrexone bromide) Research BRIDGEWATER, N.J., April 7, 2022 — Salix Pharmaceuticals (“Salix”), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) and one…
Breaking News
